[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperphosphatemia-undergoing-hemodialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperphosphatemia-undergoing-hemodialysis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100652618","real-world-efficacy-and-safety-of-tenapanor-plus-phosphate-binders-in-hemodialysis-patients-with-hyperphosphatemia-100652618",false,"NCT07776119","Real-World Efficacy and Safety of Tenapanor Plus Phosphate Binders in Hemodialysis Patients With Hyperphosphatemia","Inclusion Criteria:\n\n1. The subject has provided written informed consent prior to the initiation of any study-related activities.\n2. Male or female subjects aged ≥18 years at the time of signing the informed consent form.\n3. The subject is receiving regular maintenance hemodialysis (3 times per week, 4 hours per session) for at least 3 months.\n4. The patient has been on phosphate binder therapy for at least 3 weeks, with a stable dose.\n5. Serum phosphorus \\> 4.5 mg\u002FdL.\n\nExclusion Criteria:\n\n1. Hypersensitivity to Tenapanor or any excipients of the formulation.\n2. History of diarrhea within 1 week prior to the start of treatment. Diarrhea is defined as a Bristol Stool Form Scale (BSFS) score ≥6 (i.e., mushy or liquid stools with no solid pieces), a daily bowel movement frequency ≥3 times, and a duration of ≥2 days.\n3. Life expectancy \\\u003C 6 months.\n4. Expected or planned kidney transplantation during the study period.\n5. History of inflammatory bowel disease (IBD) or irritable bowel syndrome with diarrhea (IBS-D).\n6. Any other condition that, in the opinion of the Investigator, makes the patient unsuitable for enrollment.","ALL","18 Years","100 Years",{"count":19,"type":20},200,"ESTIMATED","6 Months","OBSERVATIONAL","The efficacy and safety of tenapanor plus PBs in Chinese patients are still unclear. Therefore, we aim to conduct a real-world study to explore the effect of combining two drugs with different mechanisms on hyperphosphatemia management.This real-world study will enroll hemodialysis patients with hyperphosphatemia who are on PBs therapy.",[25,26],"CKD 5D, Hemodialysis","Hyperphosphatemia Undergoing Hemodialysis","NOT_YET_RECRUITING","2026-08-17",{"date":30,"type":31},"2026-08-20","ACTUAL",{"date":30,"type":20},{"date":34,"type":20},"2027-10-10",{"name":36,"class":37},"Peking University People's Hospital","OTHER"]